Investigating TrkA expression in canine appendicular osteosarcoma

Journal of Veterinary Internal Medicine

Volumn 22, Issue 5, 2008, Pages 1181-1188

  Fan, Timothy M ^a   Barger, A M ^a   Sprandel, I T ^a   Fredrickson, R L ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Bone and pulmonary metastases; Bone sarcoma; Cell mitogenesis; Cellular survival signals; Receptor tyrosine kinase

Indexed keywords

NERVE PROTEIN; PROTEIN KINASE;

ANIMAL; APOPTOSIS; ARTICLE; DOG; DOG DISEASE; GENE EXPRESSION REGULATION; GENETICS; LIMB; LUNG TUMOR; METABOLISM; METASTASIS; OSTEOSARCOMA; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DOG DISEASES; DOGS; EXTREMITIES; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; NERVE TISSUE PROTEINS; OSTEOSARCOMA; PROTEIN KINASES; SIGNAL TRANSDUCTION;

CANIS FAMILIARIS;

EID: 52649091767     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0151.x     Document Type: Article

References (32)

1. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006;361:1545-1564.
2. Barbacid M, Lamballe F, Pulido D, et al. The Trk family of tyrosine protein kinase receptors. Biochim Biophys Acta 1991; 1072:115-127.
3. Nakagawara A. Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett 2001;169:107-114.
4. Hennigan A, O'Callaghan RM, Kelly AM. Neurotrophins and their receptors: Roles in plasticity, neurodegeneration and neuroprotection. Biochem Soc Trans 2007;35:424-427.
5. Asaumi K, Nakanishi T, Asahara H, et al. Expression of neurotrophins and their receptors (Trk) during fracture healing. Bone 2000;26:625-633.
6. Grills BL, Schuijers JA. Immunohistochemical localization of nerve growth factor in fractured and unfractured rat bone. Acta Orthop Scand 1998;69:415-419.
7. Kruttgen A, Schneider I, Weis J. The dark side of the NGF family: Neurotrophins in neoplasias. Brain Pathol 2006;16:304-310.
8. Pierotti MA, Greco A. Oncogenic rearrangements of the NTRK1/NGF receptor. Cancer Lett 2006;232:90-98.
9. Nakanishi T, Ohyama K, Aoki C, et al. Expression of TrkC in a mouse osteoblastic cell line and its response to neurotrophin-3. Biochem Biophys Res Commun 1994;203:1268-1274.
10. Nakanishi T, Takahashi K, Aoki C, et al. Expression of nerve growth factor family neurotrophins in a mouse osteoblastic cell line. Biochem Biophys Res Commun 1994;198:891-897.
11. Yada M, Yamaguchi K, Tsuji T. NGF stimulates differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 1994;205:1187-1193.
12. Mogi M, Kondo A, Kinpara K, et al. Anti-apoptotic action of nerve growth factor in mouse osteoblastic cell line. Life Sci 2000;67:1197-1206.
13. Pinski J, Weeraratna A, Uzgare AR, et al. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Res 2002;62:986-989.
14. Astolfi A, Nanni P, Landuzzi L, et al. An anti-apoptotic role for NGF receptors in human rhabdomyosarcoma. Eur J Cancer 2001;37:1719-1725.
15. Rende M, Brizi E, Conner J, et al. Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrKA. Int J Dev Neurosci 2000;18:869-885.
16. Rende M, Pistilli A, Stabile AM, et al. Role of nerve growth factor and its receptors in non-nervous cancer growth: Efficacy of a tyrosine kinase inhibitor (AG879) and neutralizing antibodies anti-tyrosine kinase receptor A and antinerve growth factor: An in-vitro and in-vivo study. Anticancer Drugs 2006;17:929-941.
17. Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992;200:995-999.
18. Chun R, de Lorimier LP. Update on the biology and management of canine osteosarcoma. Vet Clin North Am Small Anim Pract 2003;33:491-516, vi.
19. Shoieb AM, Hahn KA, Barnhill MA. An in vivo/in vitro experimental model system for the study of human osteosarcoma: Canine osteosarcoma cells (COS31) which retain osteoblastic and metastatic properties in nude mice. In Vivo 1998;12:463-472.
20. Kaplan DR. Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the Trk proto-oncogene product induced by NGF. Nature 1991;350:158-160.
21. Berg MM, Sternberg DW, Parada LF, et al. K-252a inhibits nerve growth factor-induced Trk proto-oncogene tyrosine phosphorylation and kinase activity. J Biol Chem 1992;267: 13-16.
22. Nye SH, Squinto SP, Glass DJ, et al. K-252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses. Mol Biol Cell 1992;3:677-686.
23. Marshall JL, Kindler H, Deeken J, et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 2005;23:31-37.
24. Collins C, Carducci MA, Eisenberger MA, et al. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther 2007;6.
25. Festuccia C, Gravina GL, Muzi P, et al. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Prostate 2007;67:1255-1264.
26. Festuccia C, Muzi P, Gravina GL, et al. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol 2007; 30:193-200.
27. Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005;115:128-141.
28. Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005;65:9426-9435.
29. Ugolini G, Marinelli S, Covaceuszach S, et al. The function neutralizing anti-TrkA antibody MNACl3 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci USA 104:2985-2990.
30. Tsunoda S, Okumura T, Ito T, et al. Significance of nerve growth factor overexpression and its autocrine loop in oesophageal squamous cell carcinoma. Br J Cancer 2006;95:322-330.
31. Renne C, Willenbrock K, Kuppers R, et al. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin's lymphoma. Blood 2005;105:4051-4059.
32. Dolle L, El Yazidi-Belkoura I, Adriaenssens E, et al. Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 2003;22:5592-5601.